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Unfortunately, the options for treating multidrug-resistant (MDR) Acinetobacter baumannii (A. 
baumannii) infections are extremely limited. Recently, fosfomycin and minocycline were newly 
introduced as a treatment option for MDR A. baumannii infection. Therefore, we investigated the 
efficacy of the combination of colistin with fosfomycin and minocycline, respectively, as therapeutic 
options in MDR A. baumannii pneumonia. We examined a carbapenem-resistant A. baumannii isolated 
from clinical specimens at Severance Hospital, Seoul, Korea. The effect of colistin with fosfomycin, and 
colistin with minocycline on the bacterial counts in lung tissue was investigated in a mouse model of 
pneumonia caused by MDR A. baumannii. In vivo, colistin with fosfomycin or minocycline significantly 
(p < 0.05) reduced the bacterial load in the lungs compared with the controls at 24 and 48 h. In the 
combination groups, the bacterial loads differed significantly (p < 0.05) from that with the more active 
antimicrobial alone. Moreover, the combination regimens of colistin with fosfomycin and colistin with 
minocycline showed bactericidal and synergistic effects compared with the more active antimicrobial 
alone at 24 and 48 h. This study demonstrated the synergistic effects of combination regimens of 
colistin with fosfomycin and minocycline, respectively, as therapeutic options in pneumonia caused by 
MDR A. baumannii.
Acinetobacter baumannii is a well-documented, multidrug-resistant (MDR) nosocomial pathogen1. In the past, 
carbapenems have been recommended as the antibiotics of choice for treating A. baumannii. However, the 
increasing incidence of MDR strains has led to use of unconventional antibiotics, such as polymyxin, rifampicin, 
and tigecycline, for the treatment of MDR isolates2. Nevertheless, pneumonia caused by MDR A. baumannii 
infection has a high mortality rate3.
Colistin has been used increasingly for the treatment of MDR A. baumannii infection, despite its potential 
nephrotoxicity and neurotoxicity. It has shown excellent in vitro antibacterial effect against carbapenem-resistant 
A. baumannii4. However, low plasma concentrations, heteroresistance and rapid regrowth after colistin treatment 
have brought the efficacy of colistin monotherapy into question5.
Consequently, colistin-based combination treatments have been proposed to attain antibiotic synergy. A 
systematic review revealed that colistin-based combinations with several antibiotics exerted a synergistic effect 
against isolates of MDR A. baumannii and lowered the mortality rate in animal studies6–11.
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Recently, minocycline and fosfomycin, two ‘old’ drugs, were newly introduced as treatment options for MDR 
A. baumannii infection. Minocycline had the second highest susceptibility rate (79.1%), followed by colistin in 
vitro12. Fosfomycin is active against Gram-positive and -negative bacteria13. Also, fosfomycin is an alternative 
agent for the treatment of MDR bacterial infections14,15.
However, to our literature search, little in vivo data are available on the use of colistin with minocycline or fos-
fomycin for the treatment of infection by MDR A. baumannii, especially pneumonia. Therefore, we investigated 
the in vivo efficacy of combinations of colistin with minocycline and fosfomycin, respectively, as therapeutic 
options in a mouse model of MDR A. baumannii pneumonia.
Results
Antibiotic susceptibility tests. Table 1 shows the minimum inhibitory concentrations (MICs) of pipera-
cillin/tazobactam, ceftazidime, imipenem, amikacin, ciprofloxacin, tigecycline, colistin, minocycline, and fosfo-
mycin of an A. baumannii isolate.
Time-kill test. At 0.5 × MIC, combinations of colistin with fosfomycin and colistin with minocycline showed 
synergistic effects, with >2 log 10 reductions in CFU at 4 and 8 h. Moreover, this reduction in CFU was maintained 
at 24 h. The combination regimens showed synergistic effects with ≥2 log10 decreases compared with the mono-
therapy regimens. The time–kill curves are shown in Fig. 1.
Mouse model of MDR A. baumannii pneumonia. Figure 2 shows the lung pathology at 4, 24, and 48 h 
after nasal inoculation. Four hours after inoculation, no significant lesion was present in the alveoli, bronchioles, 
or bronchi, except for minimal edema in the alveolar cavity. At 24 h after nasal inoculation, moderate numbers 
of neutrophils and macrophages had infiltrated the alveoli, with moderate edema, and bacterial colonization was 
observed in the alveolar cavities. At 48 h after nasal inoculation, large numbers of macrophages and neutrophils 
had infiltrated the alveoli.
Effects on lung bacterial loads. Table 2 shows the lung bacterial loads in each group. Colistin, fosfomycin, 
and minocycline significantly (p < 0.05) reduced the bacterial loads in the lungs, compared with the controls, at 
24 and 48 h. At 24 h after starting the antibiotic agents, fosfomycin and minocycline showed bactericidal effects, 
but colistin did not. However, colistin in combination with fosfomycin and minocycline, respectively, significantly 
β-lactamase*
MIC(mg/L)
PIP/
TAZ CAZ IMP AMK CIP TIG COL MIN FOS
OXA-23 >128 >128 32 >128 >128 16 0.5 0.25 >128
Table 1. Antibiotic susceptibility of carbapenemase–producing A. baumannii. MIC, minimal inhibitory 
concentration; PIP/TAZ, piperacillin/tazobactam; CAZ, ceftazidime; IMP, imipenem; AMK, amikacin; CIP, 
ciprofloxacin; TIG, tigecycline; COL, colistin; MIN, minocycline; FOS, fosfomycin. *There were no additional 
chromosomal beta-lactamase genes in this strain.
Figure 1. Time-kill curves. Colistin/fosfomycin and colistin/minocycline combinations showed bactericidal 
effects, with >3 log10 reductions in CFU at 4, 8, and 24 h. The combination regimens showed synergistic 
effects, with ≥2 log10 decreases in CFU compared with the monotherapy regimens (0.5 × MIC). (C: colistin; F: 
fosfomycin; M: minocycline).
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(p < 0.05) reduced the bacterial load in the lungs compared with the controls at 24 and 48 h. In the combination 
groups, significant (p < 0.05) differences were noted in the bacterial loads compared with the more active antimi-
crobial alone. Moreover, the combination regimens all showed bactericidal and synergistic effects at 24 and 48 h 
compared with the more active antimicrobial alone. The combination of colistin with fosfomycin significantly 
(p < 0.05) reduced the bacterial load in the lungs at 48 h compared with colistin with minocycline.
Effects on survival. Table 3 shows the mortality rates of the mice. The mortality rate was 33.3% (4/12) in 
the untreated control group at 48 h. No significant difference in survival was observed among the control and 
antibiotic-treated groups.
Discussion
This study demonstrated the synergistic effects of regimens combining colistin with minocycline and fosfomycin, 
respectively, on pneumonia caused by MDR A. baumannii.
The treatment of A. baumannii infection is an important problem in the nosocomial setting16. In serious 
infections including pneumonia, initial therapy with an appropriate antibiotic is very important6. In addition 
Figure 2. Histopathology of the lung tissues of mice at 4 (A), 24 (B), and 48 h (C) after inoculation with A. 
baumannii (H&E; bar = 100 µm). (A) At 4 h after inoculation, no significant lesion was present in the alveoli, 
bronchioles, or bronchi, except for minimal edema in the alveolar cavity. (B) At 24 h after inoculation, moderate 
numbers of neutrophils (dark triangle) and macrophages (blue triangle) had infiltrated the alveoli; moderate 
edema was present, and bacterial colonization (dark arrow) was observed in the alveolar cavities. (C) At 48 h 
after inoculation, large numbers of neutrophils (dark triangle) and macrophages (blue triangle) had infiltrated 
the alveoli.
Antibiotic regimen 24 h 48 h
Control 12.24 ± 0.44 12.99 ± 0.22
COL 9.65 ± 0.43a 8.73 ± 0.34a
FOS 7.68 ± 0.47a 6.68 ± 1.02a
MIN 9.26 ± 0.19a 7.73 ± 1.33a
COL + FOS 5.63 ± 0.26a,b 3.46 ± 0.42a,b,c
COL + MIN 6.07 ± 1.04a,b 5.16 ± 0.83a,b
Table 2. Therapeutic effects on the lung bacterial loads at 24 and 48 h after starting the antibiotic agents. COL, 
colistin; MIN, minocycline; FOS, fosfomycin. The lung bacterial loads are expressed as the mean ± standard 
deviation of log10 CFU per gram of lung at 24 and 48 h. aSignificant difference in bacterial load compared with 
the control group (p < 0.05). bSignificant difference in bacterial load compared with the more active antibiotic 
alone (p < 0.05). cSignificant difference in bacterial load compared with the other combination (p < 0.05).
Antibiotic regimen 24 h 48 h
Control 0/15 (0%) 4/12 (33.3%)
COL 0/15 (0%) 0/12 (0%)
FOS 0/15 (0%) 0/12 (0%)
MIN 0/15 (0%) 0/12 (0%)
COL + FOS 0/15 (0%) 0/12 (0%)
COL + MIN 0/15 (0%) 0/12 (0%)
Table 3. Mortality rates in the control and antibiotic-treated groups. COL, colistin; MIN, minocycline; FOS, 
fosfomycin.
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to colistin, other antibiotic regimens have emerged, although none has been fully tested. Carbapenem with sul-
bactam showed a synergistic effect against in MDR A. baumannii strains6,7. Although the study population was 
heterogeneous and small and no control group was used, a clinical study of rifampicin in combination with 
colistin and imipenem, yielded promising results8,9. Tigecycline also showed good bacteriostatic activity against 
carbapenem-resistant A. baumannii in vitro6,10. However, the synergistic activity of many antibiotics in vitro does 
not correlate with that in vivo17. Nevertheless, some specific antibiotic combinations have shown increased in vivo 
efficacy against MDR isolates18.
Recently, fosfomycin and minocycline were introduced as treatment options for the infection caused by MDR 
A. baumannii12,13. In our time–kill study, colistin with fosfomycin and minocycline, respectively, showed bacteri-
cidal and synergistic effects at 8 and 24 h. A previous study using time–kill tests documented synergistic and bac-
tericidal effects of colistin and minocycline in 92% of the strains tested at 24 h2. In another study using the E-test, 
the fractional inhibitory concentration indices (FICIs) for combinations of polymyxin B and minocycline were 
generally ≤0.5 or >0.5–1.0, suggesting that polymyxin B and minocycline have a synergistic or additive effect19. 
In the same study, most FICIs for polymyxin B and fosfomycin were within the ranges of 0.5–1.0 and 1.0–4.0, sug-
gesting that polymyxin B and fosfomycin exert an additive or independent effect19. In comparison, another study 
of combination therapy against A. baumannii found that colistin combined with fosfomycin was more effective 
than colistin monotherapy in 83.3% (24 h) and 66.7% (48 h) of MDR strains18.
We also found that colistin with minocycline and colistin with fosfomycin showed bactericidal and synergistic 
effects 24 and 48 h after nasal inoculation in vivo, in accordance with previous studies. Yang et al.20 reported that 
minocycline in combination with colistin had in vivo synergistic efficacy against MDR A. baumannii pneumonia. 
Bowers et al.21 showed that minocycline combined with polymyxin B further decreased the bacterial lung load at 
24 h, compared with monotherapy. Sirijatuphat et al.22 reported that colistin with fosfomycin showed a synergis-
tic effect against carbapenem-resistant A. baumannii. They also recently conducted a preliminary clinical study, 
which showed that patients with MDR A. baumannii infection given a combination of colistin and fosfomycin 
had significantly better microbiological responses with trends toward more favorable treatment outcomes and 
lower mortality compared with those treated with colistin alone23. However, because several types of infection, 
polymicrobial infections and concurrent antimicrobial agents were included in their study, it was heterogenous. 
Although our study was an in vivo animal study, not human study, it was more homogenous than previous study.
Interestingly, our in vivo results showed that the combination of colistin with fosfomycin significantly reduced 
the bacterial load in the lungs, compared with monotherapy and colistin with minocycline, at 48 h. Fosfomycin 
has a higher MIC against A. baumannii. For an antibiotic to be effective clinically, it must achieve concentrations 
in the interstitial fluid that exceed the MICs for the pathogens24,25. One study showed that fosfomycin achieved 
antimicrobially effective concentrations in infected lung tissue26. Also, without pharmacokinetics (PKs) of fosfo-
mycin in this study, we used it every 4 h according to other study. These frequent injections of fosfomycin might 
attain more effective concentrations in infected lung tissue than minocycline. Moreover, in the combination ther-
apy, fosfomycin was injected with colistin simultaneously, but minocycline was not. This difference explains the 
greater effectiveness of colistin with fosfomycin relative to colistin with minocycline at 48 h.
No significant difference in survival was observed among the control and antibiotic-treated groups. This find-
ing might be due to the relatively short duration of follow-up in our study or the relatively low virulence of OXA-
23 carbapenemase-producing A. baumannii. According to a previous report, OXA-23 carbapenemase-producing 
A. baumannii infection has a high mortality rate in intensive care unit patients27. Consequently, further evaluation 
of the mortality rate of OXA-23 carbapenemase-producing A. baumannii infection with a longer follow-up is 
needed.
Our study has some limitations. First, only one strain from a single center was used. However, we used an 
OXA-23 carbapenemase-producing A. baumannii isolated from clinical specimens obtained in our hospital. 
OXA-23 carbapenemase is the most common carbapenemase in South Korea28. Therefore, our study was mean-
ingful in this regard. Second, we did not investigate the PKs of the drugs used in this study. However, we used 
dosages that have been used in other studies.
In conclusion, we investigated the in vivo efficacy of colistin in combination with minocycline and fosfomycin, 
as therapeutic options in a mouse model of MDR A. baumannii pneumonia. We demonstrated the in vivo syner-
gistic effects of regimens combining colistin with minocycline and fosfomycin, on pneumonia caused by MDR A. 
baumannii. Large clinical trials are needed to clarify the role of regimens combining colistin with fosfomycin or 
minocycline in treating MDR A. baumannii pneumonia.
Methods
Bacterial strains. We obtained five carbapenem-resistant A. baumannii, which have an OXA-23 carbap-
enemase, isolated from clinical specimens obtained at Severance Hospital, Seoul, South Korea. We selected the 
most virulent strain, which was isolated from a patient with pneumonia and bacteremia. The other strains were 
colonizers isolated from sputum specimens. A strain was considered resistant to carbapenems when the MIC 
against imipenem was ≥16 mg/L.
Antibiotic susceptibility tests. Antibiotic susceptibility tests were performed in duplicate using the 
agar dilution and broth microdilution methods according to the Clinical and Laboratory Standards Institute 
(CLSI)29. The MICs of piperacillin/tazobactam, ceftazidime, imipenem, amikacin, ciprofloxacin, minocy-
cline, and fosfomycin were determined by the agar dilution method. The MICs of colistin were determined 
by the broth microdilution method. The MICs of fosfomycin were determined by the agar dilution method in 
cation-adjusted Mueller-Hinton medium, supplemented with 25 mg/L glucose-6-phosphate (Sigma-Aldrich., 
St. Louis, MO, USA). Because there are no CLSI interpretive criteria for fosfomycin against A. baumannii, the 
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fosfomycin breakpoints for Escherichia coli were used according to the CLSI guidelines29. E. coli ATCC 25922 
and Pseudomonas aeruginosa ATCC 27853 were used for quality control of antimicrobial susceptibility testing.
Detection of carbapenemase genes by PCR. After DNA extraction multiplex PCR was performed 
to detect blaOXA genes (blaOXA-23-like, blaOXA-24-like, and blaOXA-58-like genes) and ISAba1-associated 
blaOXA-51-like gene30. Additionally, PCR was performed to detect blaOXA-182 gene31. We performed PCR to 
detect blaIMP-1-like, blaVIM-2-like, and blaSIM-1-like genes32. Sequence analysis was performed by a commer-
cial laboratory (Macrogen, Seoul, South Korea).
Time–kill test. For both agents and their combinations, time–kill tests were performed using sub-inhibitory 
For both agents and their combinations, (0.5 × MIC)33. Ten-fold dilutions were inoculated onto Mueller–Hinton 
agar and colonies were counted at 0, 4, 8, and 24 h. Bactericidal activity was defined as a ≥3 log10 decrease com-
pared with the initial inoculum. Synergy was defined as a ≥2 log10 decrease with the combination, compared with 
most active single agent34. Experiments were performed in triplicate on separate days. Results were read by two 
observers.
Mouse model of MDR A. baumannii pneumonia. The animal study was approved by the Institutional 
Animal Care and Use Committee of the Yonsei University College of Medicine (#2014-0275). All animal 
experimental protocols were performed in accordance with the relevant ethical guidelines and regulations. 
Immunocompetent, specific pathogen–free, 6-week-old female mice weighing 18–20 g (C57BL/6N) were used 
(Orient Bio, Seongnam, South Korea). Animals were rendered transiently neutropenic by injecting cyclophospha-
mide intraperitoneally (300 mg/kg body weight) in a volume of 0.2 mL 4 days before A. baumannii inoculation in 
the lung. The mice were anesthetized by intraperitoneal injection of 100 mg/kg ketamine and 10 mg/kg xylazine. 
Then, 1.2 mL/kg of a 5 × 108 colony-forming units (CFU)/mL bacterial suspension was inoculated through the 
nose using a syringe35. After being kept in a vertical position for 4 min, the mice were maintained in a 30° decu-
bitus position until regaining consciousness. Necropsy was performed on one mouse at 4, 24, and 48 h after the 
nasal inoculation. The entire lung was removed in a sterile fashion and evaluated pathologically, and the diagnosis 
of pneumonia was confirmed. Sterile lung specimens were fixed in 10% formalin and immersed in paraffin wax. 
Specimens were prepared in 5-μm cross sections and were examined under a light microscope after hematoxylin/
eosin staining.
Study groups. The mice with pneumonia were randomized into six groups of 15 mice each five treatment 
groups and a control group. Colistin was administered to the first group, fosfomycin to the second, minocycline 
to the third, the colistin/fosfomycin combination to the fourth, and the colistin/minocycline combination to the 
fifth. No antibacterial agent was administered to the mice in the control group. After the experiment, the mice 
were euthanized by CO2 inhalation.
Treatment protocol. Treatments were initiated 4 h after nasal inoculation. The antibiotic agents were given 
by intraperitoneal injection at the following dosages: colistin, 20 mg/kg every 8 h36, fosfomycin, 100 mg/kg every 
4 h37, and minocycline, 20 mg/kg every 12 h38. Colistin, fosfomycin, and minocycline were purchased from 
Sigma-Aldrich.
Effects on lung bacterial loads. Bacteria in the lungs of three mice were counted 24 and 48 h after start-
ing the antibiotic administration. To eliminate any antibiotic carry-over effect, mice in the treatment groups 
were euthanized at least 3 h after the last antibiotic dose. For quantitative bacteriological studies, the lungs were 
removed, weighed, and homogenized in 1 mL of saline. Tenfold dilutions were made, and 100-μL aliquots were 
plated on tryptic soy agar with 5% sheep blood plates for 24 h at 37 °C. Colonies were counted for each dilution 
and each animal. Experiments were performed in triplicate. The results are expressed as means ± standard devi-
ation (SD) log10 CFU per gram lung at 24 and 48 h, and differences between groups were calculated as follows: 
mean of the treated group – mean of the control group. Bactericidal activity was defined as a ≥3 log10 decrease 
compared with the initial inoculum. Synergy was defined as a ≥2 log10 decrease in killing by the combination 
compared with the most active single drug alone18.
Effects on survival. The survival rates of all mice at 24 and 48 h were recorded and compared among the 
treatment and control groups.
Statistical analysis. All bacterial counts are presented as the mean ± SD. Student’s t-test was used to analyze 
inter-group differences in the bacterial counts. To compare mortality between groups, Fisher’s exact test was used. 
In all tests, differences were considered to be statistically significant when the p-value was <0.05.
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